Daniel M Moreira1, Lauren E Howard2, Katharine N Sourbeer3, Hiruni S Amarasekara3, Lydia C Chow3, Dillon C Cockrell3, Brian T Hanyok3, William J Aronson4, Christopher J Kane5, Martha K Terris6, Christopher L Amling7, Matthew R Cooperberg8, Alex Liede9, Stephen J Freedland10. 1. Department of Urology, Mayo Clinic, Rochester, MN. Electronic address: moreira.daniel@mayo.edu. 2. Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, NC; Urology Section, Veterans Affairs Medical Center, Durham, NC. 3. Urology Section, Veterans Affairs Medical Center, Durham, NC. 4. Urology Section, Department of Surgery, Veterans Affairs Medical Center, Greater Los Angeles, Los Angeles, CA; Department of Urology, University of California at Los Angeles Medical Center, Los Angeles, CA. 5. Division of Urology, Department of Surgery, University of California at San Diego Medical Center, San Diego, CA. 6. Urology Section, Division of Surgery, Veterans Affairs Medical Centers, Augusta, GA; Division of Urologic Surgery, Department of Surgery, Medical College of Georgia, Augusta, GA. 7. Division of Urology, Department of Surgery, Oregon Health & Science University, Portland, OR. 8. Departments of Urology and Epidemiology & Biostatistics, University of California, San Francisco, CA; Urology Section, Department of Surgery, Veterans Affairs Medical Center, San Francisco, CA. 9. Amgen Inc., Royal Oaks, MI. 10. Urology Section, Veterans Affairs Medical Center, Durham, NC; Division of Urology, Department of Surgery, Cedars Sinai Medical Center, Los Angeles, CA.
Abstract
OBJECTIVE: To investigate predictors of time to metastasis among men treated with androgen deprivation therapy for nonmetastatic prostate cancer who developed castration-resistant prostate cancer (CRPC) within the Shared Equal Access Regional Cancer Hospital cohort. METHODS: This is a retrospective analysis of 458 nonmetastatic CRPC men. Metastases were detected in routine bone scans or other imaging tests. Predictors of time to metastasis were analyzed using proportional hazards model with CRPC as time zero. RESULTS: A total of 256 (56%) men were diagnosed with metastatic disease over a median follow-up of 36 months. Metastasis-free survival was 79%, 65%, 52%, 47%, and 41% at 1, 2, 3, 4, and 5 years after CRPC, respectively. In multivariable analysis, Gleason score 8-10 (hazard ratio [HR] = 1.61; P = .026), receiving primary localized treatment (HR = 1.38; P = .028), higher prostate-specific antigen (PSA) levels at CRPC diagnosis (logPSA HR = 1.64; P < .001), and PSA doubling time ≤6 months (HR = 1.42; P = .040) were independently associated with shorter time to metastasis. Race, year of CRPC, age, and time from androgen deprivation therapy to CRPC were not associated with metastasis. CONCLUSION: Among nonmetastatic CRPC men, nearly 60% developed metastatic disease during the first 5 years, with most of the metastasis occurring within the first 3 years. Higher Gleason score, receiving primary treatment, higher PSA, and shorter PSA doubling time were independently associated with shorter time to metastasis. Therefore, these variables can be used to stratify patients according to metastasis risk.
OBJECTIVE: To investigate predictors of time to metastasis among men treated with androgen deprivation therapy for nonmetastatic prostate cancer who developed castration-resistant prostate cancer (CRPC) within the Shared Equal Access Regional Cancer Hospital cohort. METHODS: This is a retrospective analysis of 458 nonmetastatic CRPC men. Metastases were detected in routine bone scans or other imaging tests. Predictors of time to metastasis were analyzed using proportional hazards model with CRPC as time zero. RESULTS: A total of 256 (56%) men were diagnosed with metastatic disease over a median follow-up of 36 months. Metastasis-free survival was 79%, 65%, 52%, 47%, and 41% at 1, 2, 3, 4, and 5 years after CRPC, respectively. In multivariable analysis, Gleason score 8-10 (hazard ratio [HR] = 1.61; P = .026), receiving primary localized treatment (HR = 1.38; P = .028), higher prostate-specific antigen (PSA) levels at CRPC diagnosis (logPSA HR = 1.64; P < .001), and PSA doubling time ≤6 months (HR = 1.42; P = .040) were independently associated with shorter time to metastasis. Race, year of CRPC, age, and time from androgen deprivation therapy to CRPC were not associated with metastasis. CONCLUSION: Among nonmetastatic CRPC men, nearly 60% developed metastatic disease during the first 5 years, with most of the metastasis occurring within the first 3 years. Higher Gleason score, receiving primary treatment, higher PSA, and shorter PSA doubling time were independently associated with shorter time to metastasis. Therefore, these variables can be used to stratify patients according to metastasis risk.
Authors: Andrew J Armstrong; Elizabeth Garrett-Mayer; Ronald de Wit; Ian Tannock; Mario Eisenberger Journal: Clin Cancer Res Date: 2009-12-15 Impact factor: 12.531
Authors: Ethan Basch; Karen Autio; Charles J Ryan; Peter Mulders; Neal Shore; Thian Kheoh; Karim Fizazi; Christopher J Logothetis; Dana Rathkopf; Matthew R Smith; Paul N Mainwaring; Yanni Hao; Thomas Griffin; Susan Li; Michael L Meyers; Arturo Molina; Charles Cleeland Journal: Lancet Oncol Date: 2013-09-25 Impact factor: 41.316
Authors: Maha Hussain; Bryan Goldman; Cathy Tangen; Celestia S Higano; Daniel P Petrylak; George Wilding; Atif M Akdas; Eric J Small; Bryan J Donnelly; Subramanian Kanaga Sundram; Patrick A Burch; Robert S Dipaola; E David Crawford Journal: J Clin Oncol Date: 2009-04-20 Impact factor: 44.544
Authors: Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger Journal: N Engl J Med Date: 2004-10-07 Impact factor: 91.245
Authors: Fred Saad; Donald M Gleason; Robin Murray; Simon Tchekmedyian; Peter Venner; Louis Lacombe; Joseph L Chin; Jeferson J Vinholes; J Allen Goas; Bee Chen Journal: J Natl Cancer Inst Date: 2002-10-02 Impact factor: 13.506
Authors: Karim Fizazi; Howard I Scher; Kurt Miller; Ethan Basch; Cora N Sternberg; David Cella; David Forer; Mohammad Hirmand; Johann S de Bono Journal: Lancet Oncol Date: 2014-08-04 Impact factor: 41.316
Authors: Howard I Scher; Susan Halabi; Ian Tannock; Michael Morris; Cora N Sternberg; Michael A Carducci; Mario A Eisenberger; Celestia Higano; Glenn J Bubley; Robert Dreicer; Daniel Petrylak; Philip Kantoff; Ethan Basch; William Kevin Kelly; William D Figg; Eric J Small; Tomasz M Beer; George Wilding; Alison Martin; Maha Hussain Journal: J Clin Oncol Date: 2008-03-01 Impact factor: 44.544
Authors: D M Moreira; L E Howard; K N Sourbeer; H S Amarasekara; L C Chow; D C Cockrell; B T Hanyok; C L Pratson; W J Aronson; C J Kane; M K Terris; C L Amling; M R Cooperberg; A Liede; S J Freedland Journal: Prostate Cancer Prostatic Dis Date: 2015-05-26 Impact factor: 5.554
Authors: Stefan Holmstrom; Shevani Naidoo; James Turnbull; Emily Hawryluk; Jean Paty; Robert Morlock Journal: Patient Date: 2019-02 Impact factor: 3.883
Authors: Rebecca Morgan; Willian Abraham da Silveira; Ryan Christopher Kelly; Ian Overton; Emma H Allott; Gary Hardiman Journal: Expert Rev Mol Diagn Date: 2021-11-25 Impact factor: 5.225
Authors: Alexander C Bunck; Daniel Pinto Dos Santos; De-Hua Chang; Marcel Reiser; David Pfister; Anne Bunck; Alexander Drzezga; David Maintz; Matthias Schmidt Journal: Case Rep Oncol Date: 2017-07-11